TickerFacts.

A business in context

CLYM research notebook

Read the disclosures. Follow the relationships. Keep the dates in view.

Research JSON

Filing timeline

Download filings CSV

SEC submissions · retrieved 2026-10-23 · 8022 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer

  1. 4 · Ownership change

    Report date 2026-09-28 · 0001231919-26-001416

  2. 4 · Ownership change

    Report date 2026-09-15 · 0001193125-26-394357

  3. 8-K · Current report

    Report date 2026-09-03 · 0001193125-26-381060 · Items 7.01,9.01

  4. 8-K · Current report

    Report date 2026-08-13 · 0001193125-26-350596 · Items 8.01

  5. 10-Q · Quarterly report

    Report date 2026-06-30 · 0001193125-26-336774

  6. 8-K · Current report

    Report date 2026-08-06 · 0001193125-26-336762 · Items 2.02,9.01

  7. 4 · Ownership change

    Report date 2026-06-29 · 0001231919-26-000722

  8. 4 · Ownership change

    Report date 2026-06-29 · 0001193125-26-292640

  9. 8-K · Current report

    Report date 2026-06-29 · 0001193125-26-292567 · Items 5.02

  10. 4 · Ownership change

    Report date 2026-06-27 · 0001193125-26-291131

  11. 8-K · Current report

    Report date 2026-06-11 · 0001193125-26-269567 · Items 1.01,8.01,9.01

  12. 8-K · Current report

    Report date 2026-06-11 · 0001193125-26-266688 · Items 8.01

  13. 4 · Ownership change

    Report date 2026-06-05 · 0001231919-26-000610

  14. 4 · Ownership change

    Report date 2026-06-05 · 0001193125-26-262292

  15. 4 · Ownership change

    Report date 2026-06-05 · 0001193125-26-262290

  16. 8-K · Current report

    Report date 2026-06-05 · 0001193125-26-261716 · Items 5.02,5.07,9.01

  17. 8-K · Current report

    Report date 2026-06-05 · 0001193125-26-258372 · Items 8.01

  18. 10-Q · Quarterly report

    Report date 2026-03-31 · 0001193125-26-210357

  19. 8-K · Current report

    Report date 2026-05-07 · 0001193125-26-210295 · Items 2.02,9.01

  20. 8-K · Current report

    Report date 2026-05-05 · 0001193125-26-205079 · Items 7.01,9.01

  21. 8-K · Current report

    Report date 2026-04-27 · 0001193125-26-183711 · Items 1.01,3.02,8.01,9.01

  22. DEF 14A · Proxy statement

    Report date 2026-06-05 · 0001193125-26-177271

  23. 8-K · Current report

    Report date 2026-04-01 · 0001193125-26-142114 · Items 5.02

  24. 10-K · Annual report

    Report date 2025-12-31 · 0001193125-26-092546

  25. 8-K · Current report

    Report date 2026-03-05 · 0001193125-26-092520 · Items 2.02,9.01

  26. 8-K · Current report

    Report date 2026-01-08 · 0001193125-26-006994 · Items 7.01,8.01,9.01

  27. 8-K · Current report

    Report date 2025-12-31 · 0001193125-25-338318 · Items 8.01,9.01

  28. 8-K · Current report

    Report date 2025-12-11 · 0001193125-25-315108 · Items 1.01,3.02,9.01

  29. 10-Q · Quarterly report

    Report date 2025-09-30 · 0001193125-25-268086

  30. 8-K · Current report

    Report date 2025-11-06 · 0001193125-25-268075 · Items 2.02,9.01

  31. 8-K · Current report

    Report date 2025-10-17 · 0001193125-25-241951 · Items 8.01

  32. 8-K · Current report

    Report date 2025-09-30 · 0001193125-25-227025 · Items 5.02,9.01

  33. 8-K · Current report

    Report date 2025-09-29 · 0001193125-25-221756 · Items 7.01,8.01,9.01

  34. 10-Q · Quarterly report

    Report date 2025-06-30 · 0000950170-25-106916

  35. 8-K · Current report

    Report date 2025-08-12 · 0000950170-25-106913 · Items 2.02,9.01

  36. 8-K · Current report

    Report date 2025-06-12 · 0001193125-25-142359 · Items 5.02

  37. 8-K · Current report

    Report date 2025-06-04 · 0001193125-25-135864 · Items 5.07

  38. 8-K · Current report

    Report date 2025-05-23 · 0001193125-25-125866 · Items 5.02,9.01

  39. 10-Q · Quarterly report

    Report date 2025-03-31 · 0000950170-25-070902

  40. 8-K · Current report

    Report date 2025-05-14 · 0000950170-25-070901 · Items 2.02,9.01

Reported insider transactions

Download transactions CSV

SEC insider transactions · retrieved 2026-10-23 · 2026 Q3: filings in this completed quarter; not a live transaction feed

Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.

Transaction rows by code · counts, not monetary totals
Purchase: 0 transaction rows0PSale: 1 transaction rows1SGrant / award: 2 transaction rows2AExercise / conversion: 8 transaction rows8MTax / exercise payment: 0 transaction rows0FGift: 0 transaction rows0G
P · PurchaseS · SaleA · Grant / awardM · Exercise / conversionF · Tax / exercise paymentG · Gift

11 matching transaction rows.

Transaction / filedReporting ownerTypeSecuritySharesReported price
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Acquired
Common Stock10000.07.89
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Acquired
Common Stock40000.01.29
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Acquired
Common Stock10000.03.46
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Acquired
Common Stock10000.03.0
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
10000.00.0
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
10000.00.0
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
40000.00.0
2026-09-28
2026-09-30
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.M · Exercise / conversion
Disposed
Stock Option (Right to Buy)
Derivative security
10000.00.0
2026-09-15
2026-09-17
Thomas Stephen BasilS · Sale
Disposed
Common Stock100000.013.67
2026-06-29
2026-07-01
Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund, L.P.; Shah Rajeev M.A · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
70284.00.0
2026-06-29
2026-07-01
Celebi Breanna MaurineA · Grant / award
Acquired
Stock Option (Right to Buy)
Derivative security
70284.00.0

Identity & relationships

Wikidata structured data · retrieved 2026-10-23 · 1658 unambiguous CIK-linked entities; coverage is incomplete

These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.

SEC issuer · 0001768446Climb Bio, Inc.

No parent relationship is available in this import; this is not proof of independence.

No verified LEI join available.

GLEIF legal entity reference data · retrieved 2026-10-23 · 1197 checked identities; 0 unavailable records

Search names and former names
  • Eliem Therapeutics, Inc. · former SEC name · 2019-02-19 to 2024-09-20

Revenue in constant purchasing power

USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.

No USD annual revenue periods with complete CPI coverage are available. Non-USD statements are not converted with U.S. CPI.

Bureau of Labor Statistics · retrieved 2026-10-23 · 9 selected series; gaps remain missing

Explore the CPI history ↗